Bone Therapeutics announces private placement of convertible bonds


Bone Therapeutics (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases (the "Company"), today announces a private placement (the “Offering”) of senior, unsecured convertible bonds (the “CBs”).

The book building process commenced yesterday, 6 March 2018, after market close. The results of the Offering will be announced as soon as possible after the closing of the book building in a subsequent press release.

Trading in the Company's shares on Euronext Brussels and Euronext Paris will be suspended during the book building period and trading in the stock is expected to resume following the publication of the results of the Offering.


Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies,
Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas
targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into
“osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive

The Company’s primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors,
which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell
therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine
patent families. Further information is available at:



Interested in a regular update of the Life Sciences and biotech sector in Flanders?